Nevertheless, other studies reported that plerixafor (either with G-CSF alone or in association with chemotherapy) elicits a lower rate of collection of sufficient transplant doses and lower CD34+ cell yield in patients with non-Hodgkin lymphoma compared to patients with either MM or HL [27,28,29,39]. Here, CD34 is linked to Hodgkins lymphoma.